Blood levels of stable nitric oxide metabolites in metabolic syndrome and diabetes mellitus
https://doi.org/10.14341/2072-0351-5457
Abstract
Aim.
To measure stable metabolites of nitric oxide (SMNO), i.e. nitrites and nitrates, and compare the results with other biochemical characteristicsof blood in patients with type 1 and 2 diabetes mellitus (DM1 and DM2) or metabolic syndrome (MS).
Materials and methods.
The following parameters were measured in 61 patients with DM, 12 with obesity, 8 with impaired glucose tolerance (IGT),and 12 healthy subjects: blood glucose level (fasting and 2 hr postprandially), HbA1c, insulin, C-peptide, SMNO, lipid spectrum, erythrocyte sialidaseactivity (ESA), and insulin resistance index (HOMA).
Results.
Postprandial glycemia was elevated in DM1, DM2, and IGT patients, HOMA in those with DM2 and IGT, ESA in all DM and MS patients.SMNO level was reduced in all groups especially in patients with DM and diabetic nephropathy. It negatively correlated with total cholesterol, TG,LDL, and ESA.
Conclusion.
Blood SMNO level as an indicator of endothelial dysfunction is of high diagnostic value starting from the early stages of impaired carbohydratemetabolism.
To measure stable metabolites of nitric oxide (SMNO), i.e. nitrites and nitrates, and compare the results with other biochemical characteristicsof blood in patients with type 1 and 2 diabetes mellitus (DM1 and DM2) or metabolic syndrome (MS).
Materials and methods.
The following parameters were measured in 61 patients with DM, 12 with obesity, 8 with impaired glucose tolerance (IGT),and 12 healthy subjects: blood glucose level (fasting and 2 hr postprandially), HbA1c, insulin, C-peptide, SMNO, lipid spectrum, erythrocyte sialidaseactivity (ESA), and insulin resistance index (HOMA).
Results.
Postprandial glycemia was elevated in DM1, DM2, and IGT patients, HOMA in those with DM2 and IGT, ESA in all DM and MS patients.SMNO level was reduced in all groups especially in patients with DM and diabetic nephropathy. It negatively correlated with total cholesterol, TG,LDL, and ESA.
Conclusion.
Blood SMNO level as an indicator of endothelial dysfunction is of high diagnostic value starting from the early stages of impaired carbohydratemetabolism.
References
1. Аляви А.Л., Розиходжаева Г.А. Дисфункция эндотелия: патогенез, возможности коррекции у больных ишемической болезнью сердца пожилого и старческого возраста. Руководство для врачей. Ташкент, 2005, 68 с.
2. Blann A.D., Woywodt A., Bertolini F., Bull T.M., Buyon J.P., Clancy R.M. et al. Circulating endothelial cells. Biomarker of vascular disease //Thromb Haemost 2005; 93: Р. 228-235.
3. Bhagat K., Vallance P. Effects of cytokines on nitric oxide pathways in human vasculature. Curr Opin Nephrol Hypertens, 1999. 8 :Р. 89 -96.
4. Lusher T.F., Barton M. Biology of the endothelium //Clin. Cardiol, 1997; 10 (suppl 11), II - 3-II-10.
5. Maeda H., Akaike T., Yoshida M., Sato K., Noguchi Y. (1995) in The Role of Nitric Oxide in Physiology and Pathophysiology (Koprowski H., and Maeda H., eds.) Springer-Verlag, Berlin, Heidelberg, Р. 37-50.
6. Vane J.R., Anggard E.E., Batting R.M. Regulatory functions of the vascular endotnelium //New England Journal of Medicine, 1990: 323: Р. 27- 36.
7. Hink Ulrich, Huige Li, Hanke Mollnau, Mathias Oelze, Edi Matheis, Mark Hartmann, Mikhail Skatchkov, Friedrich Thaiss, Rolf A. K. Stahl, Ascan Warnholtz, Thomas Meinertz, Kathy Griendling, David G. Harrison, Ulrich Forstermann, Thomas Munzel. Mechanisms Underlying Endothelial Dysfunction in Diabetes Mellitus //Circulation Research. 2001;88:e14.
8. Mather Kieren J., Mirzamohammadi Bahram, Lteif Amale, Steinberg Helmut O., Baron Alain D. Endothelin Contributes to Basal Vascular Tone and Endothelial Dysfunction in Human Obesity and Type 2 Diabetes //Diabetes, 2002, 51: Р. 3517-3523.
9. Акбаров З.С., Шамансурова З.М., Алиханова Н.М., Каюмова Д., Ахмедова М.Х. Метаболический синдром - как ранний этап развития сахарного диабета //Проблемы биологии и медицины 2005, 2, C. 30-33.
10. Alberti G., Zimmet P., Shaw J. Metabolic syndrome - a new world wide definition //Diab. Met. 2006, N23, P. 469-480.
11. WHO Technical reports series. Diabetes Mellitus: definition, classification, treatment. Geneva, Switherland, 2002.
12. Данилова Л.А., Лопатина Н.И. Колориметрический метод определения гликозилированных гемоглобинов. //Лаб.дело.- 1986.- N5.- С. 281-285.
13. Лабораторные методы исследования в клинике. Справочник./ Под ред. Меньшикова В.В. - М. : Медицина, 1987, 368 с.
14. Алексеев В.Н. Курс качественного химического полумикроанализа. М.:- Госхимиздат, 1962. - 584 с.
15. Moshage H., Kok B., Huizenga J.R., Jansen P.L.M. (1995) Nitrite and nitrate determinations in plasma: a critical evaluation //Clin. Chem. 41, Р. 892-896.
16. Shamansurova Z.M., Ergashova M.J., Akbarov Z.S. Erythrocyte sialidase activity increase in patients with diabetes mellitus //Diabetes Nutr Metab. 1998;11: Р. 257-259.
17. Aminoff D., Bell W.C., Fulton I., Ingebrightsen N. Effect of sialidase on the viability of erythrocytes in circulation //Am. J. Haematol. 1976;1: Р. 419-432.
18. Мерков А.М., Поляков Л.Е. Санитарная статистика (пособие для врачей).- Л.: Медицина, 1974, 384 с.
19. Porte D.Jr., Kahn S.E. Beta-Cell Dysfunction and Failure in Type 2 Diabetes: Potential Mechanisms //Diabetes. 2001;50(suppl 1): S160-S163.
20. Zavaroni I., Platti P.M., Monti L.D., Gasparini P., Barilli L.A., Massironi P., Ardigo D., Valsecchi G., Delsignore R., Reaven G.M. Plasma nitric oxide concentrations are elevated in insulin-resistant healthy subjects //Metabolism, 2000 49: Р. 959-961.
21. Crook M.A., Picup J.C., Lumb P.J., Georgino F., Webb D.J., Fuller J.H. The Eurodiab Complications Study. Relationship Between plasma sialic acid concentration and microvascular and macrovascular complications in type I Diabetes //Diabetes Care, 2001, 24: Р. 316-322.
22. Meuillet E.J., Kroes R., Yamamoto Hirotaka, Warner Thomas G., Ferrari Jeffry, Mania-Farnell Barbara, George David, Rebbaa Abdelhadi, Moskal Joseph R. and Bremer2 Eric G. Sialidase Gene Transfection Enhances Epidermal Growth Factor Receptor Activity in an Epidermoid Carcinoma Cell Line, A43. //Cancer Research 59, Р. 234-240, January 1, 1999.
23. Salhanick A.I., Amatruda J.M. Role of sialic acid in insulin action and the insulin resistance of diabetes mellitus //Am J Physiol. 1988; 255: Р. 173-179.
24. Schauer R. Chemistry, metabolism and biological functions of sialic acid //Adv Carbohydr Chem Biochem. 1982;40: Р. 131-143.
25. Jancik J., Schauer R. Sialic acid a determinant of the life-time of rabbit erythrocytes //Hoppe Seylers Z Physiol Chem. 1974; Р. 335: Р. 395-401.
26. Krebs J.D., Browning L.M., Cooke J.H., O'Connell M.A., Mishra G.D., Jebb S.A.; MRC Human Nutrition Research, Cambridge, United Kingdom. Elevated sialic acid predicts features of the metabolic syndrome //EASD 2002, Р. 41.
27. Lash J.M., Nase G.P., and Bohlen H.G. Acute hyperglycemia depresses arteriolar NO formation in skeletal muscle //Am J. Physiol Heart Circ Physiol, 1999, 277: Р. 1513-1520.
Review
For citations:
Shamansurova Z.M. Blood levels of stable nitric oxide metabolites in metabolic syndrome and diabetes mellitus. Diabetes mellitus. 2009;12(3):71-74. (In Russ.) https://doi.org/10.14341/2072-0351-5457
Views:
759
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND 4.0).
Email this article 
